The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
How can cytogenetics predict response to venetoclax and azacitidine in MDS?
Featured:
Jacqueline S. GarciaDuring the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US. We asked, How can cytogenetics predict response to venetoclax and azacitidine in MDS?
How can cytogenetics predict response to venetoclax and azacitidine in MDS?
Venetoclax is an orally bioavailable BCL-2 inhibitor that has demonstrated promising efficacy in combination with azacitidine. Here, Jacqueline Garcia discusses the ongoing phase Ib clinical trial, M15531 (NCT02942290), evaluating the safety and efficacy of venetoclax + azacitidine in patients with treatment-naïve, higher-risk MDS, and subgroup analyses.